Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel

CONCLUSION: The conditional OS for patients undergoing docetaxel chemotherapy tends to plateau over time, with the main drop in conditional OS happening during the first year from initiating docetaxel treatment. That is the longer a patient survives, the more likely they are to survive further. This prognostic information could be a useful tool for a more accurate tailoring of both follow-up and therapies.PATIENT SUMMARY: In this report, we looked at the future survival in months of patients with metastatic castration resistant prostate cancer on chemotherapy who have already survived a certain period. We found that the longer time that a patient survives, the more likely they will continue to survive. We conclude that this information will help physicians tailor follow-ups and treatments for patients for a more accurate personalized medicine.PMID:37290911 | DOI:10.1002/pros.24583

Source: Cancer Control - June 8, 2023 Category: Cancer & Oncology Authors: Daniele Modonutti Sami E Majdalany Mohit Butaney Matthew J Davis Nicholas Corsi Akshay Sood Quoc-Dien Trinh Alexander P Cole Craig G Rogers Giacomo Novara Firas Abdollah Source Type: research